Acme Medical Imaging Custom Case Solution & Analysis

Evidence Brief: Acme Medical Imaging (AMI)

1. Financial Metrics

Revenue Distribution: Direct sales contribute 70 percent of total annual revenue. Distributor-led sales account for the remaining 30 percent but show a 15 percent year-over-year growth rate compared to 4 percent for direct channels.
Margin Profile: Direct sales maintain a 42 percent gross margin. Distributor sales yield a 28 percent gross margin after accounting for the 15 to 20 percent discount provided to channel partners.
Sales Cost: The cost of maintaining a direct sales representative averages 220,000 dollars annually including base, commission, and travel. Distributor management costs are 45,000 dollars per partner.
Market Opportunity: Tier 3 facilities (private clinics) represent a 400 million dollar untapped market segment with high sensitivity to equipment uptime and lower sensitivity to advanced software features.

2. Operational Facts

Sales Force Structure: 45 direct sales representatives focused primarily on Tier 1 and Tier 2 hospitals. 12 independent distributors covering rural territories and Tier 3 clinics.
Sales Cycle: Tier 1 academic hospitals average 14 months. Tier 3 clinics average 4 months.
Service Model: Direct sales include a 2-year service contract. Distributor sales often rely on third-party maintenance providers, leading to inconsistent uptime reports.
Geography: Direct reps are concentrated in top 20 metropolitan areas. Distributors cover 80 percent of the remaining geographic landmass.

3. Stakeholder Positions

David Sterling (CEO): Concerned about flatlining growth in the hospital segment. Views distributors as the primary engine for reaching the high-growth Tier 3 market.
Sarah Jenkins (VP Sales): Believes the direct sales force is the brand's primary asset. Argues that distributors lack the technical expertise to sell high-end CT and MRI units.
Independent Distributors: Expressing frustration over direct reps poaching leads in Tier 2 hospitals once the distributor has done the initial prospecting work.
Tier 1 Hospital Procurement: Prefers direct relationships for customized software integration and long-term research partnerships.

4. Information Gaps

The case does not provide the specific turnover rate for direct sales staff following the introduction of the distributor program.
Detailed breakdown of marketing spend allocated to distributor support versus direct lead generation is absent.
Customer satisfaction scores (NPS) are not segmented by sales channel.

Strategic Analysis

1. Core Strategic Question

How can AMI restructure its multi-channel sales model to eliminate internal competition and capture the high-growth Tier 3 segment without eroding the high-margin Tier 1 business?

2. Structural Analysis

The current conflict stems from overlapping incentives and lack of clear account ownership. Using a Value Chain lens, AMI is currently duplicating efforts in the marketing and sales phases for Tier 2 accounts. The bargaining power of buyers in Tier 1 is high, necessitating the high-touch direct model. However, in Tier 3, the key success factor is speed and local presence, where the direct model is too expensive and slow.

3. Strategic Options

Option 1: Pure Direct Model. Eliminate all distributors. Focus exclusively on high-margin Tier 1 and Tier 2 accounts.

Rationale: Protects brand integrity and ensures high technical competence in every sale.
Trade-offs: Cedes the 400 million dollar Tier 3 market to competitors. High fixed costs remain a risk during market downturns.
Resource Requirements: Expansion of direct sales force by 20 percent to cover rural Tier 2 sites.

Option 2: Hard-Segmented Hybrid Model. Assign Tier 1 and Tier 2 accounts (over 200 beds) exclusively to direct sales. Assign all Tier 3 clinics and hospitals under 200 beds exclusively to distributors.

Rationale: Eliminates channel conflict by creating clear boundaries based on customer size and complexity.
Trade-offs: Potential loss of revenue if a distributor identifies a Tier 2 lead but cannot close it due to technical limitations.
Resource Requirements: Implementation of a shared CRM and a new commission structure that rewards direct reps for assisting distributors on complex Tier 3 deals.

4. Preliminary Recommendation

AMI should adopt the Hard-Segmented Hybrid Model. The current growth in Tier 3 is too significant to ignore, but the direct sales force is too costly to deploy there. By formalizing account ownership, AMI protects its core hospital revenue while incentivizing distributors to penetrate the private clinic market. Success requires a non-compete clause in distributor contracts and a lead-referral fee for direct reps.

Implementation Roadmap

1. Critical Path

Month 1: Audit all active leads and assign them to either the direct or distributor bucket based on the 200-bed threshold.
Month 2: Roll out the new Rules of Engagement. This includes a mandatory lead-registration system where distributors must log prospects within 48 hours.
Month 3: Realign the compensation plan. Introduce a 3 percent finders fee for direct reps who pass Tier 3 leads to distributors and a 5 percent technical support fee for assisting in distributor closes.

2. Key Constraints

Channel Trust: Distributors are currently skeptical of AMI leadership. Any violation of the new boundaries by direct reps in the first 90 days will result in distributor churn.
Technical Parity: Distributors need rapid training on the new MRI software updates to maintain the brand standard in Tier 3 clinics.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of direct sales rep flight, the transition will include a 6-month commission bridge. If a rep loses a Tier 2 account to a distributor during the re-segmentation, they receive a one-time transition payment. This prevents a sudden drop in earnings and maintains morale during the structural shift. If distributor sales do not hit the 10 percent quarterly growth target, the Tier 2 boundary will be re-evaluated.

Executive Review and BLUF

1. BLUF

AMI must immediately implement a hard-segmented hybrid sales model. Direct sales will focus exclusively on Tier 1 and Tier 2 hospitals with over 200 beds. Independent distributors will have sole rights to Tier 3 clinics and smaller facilities. The current channel conflict is cannibalizing margins and stalling growth in the high-potential private clinic segment. By establishing clear account ownership and a cross-channel referral fee, AMI will protect its 42 percent direct margins while capturing the 15 percent growth in the distributor channel. This transition must be completed within 90 days to prevent distributor defection to competitors.

2. Dangerous Assumption

The analysis assumes that independent distributors possess or can quickly acquire the technical proficiency required to sell and support AMI medical imaging equipment without damaging the brand reputation in Tier 3 markets. If distributor technical failure leads to equipment downtime, the long-term cost of lost service contracts will outweigh the growth gains.

3. Unaddressed Risks

Sales Force Attrition: Top-performing direct reps may view the loss of Tier 3 territory as a permanent pay cut and move to GE or Siemens. Probability: High. Consequence: Loss of Tier 1 relationship continuity.
Data Integrity: The plan relies on a shared CRM. If distributors refuse to log their leads for fear of poaching, the lead-registration system fails. Probability: Moderate. Consequence: Continued channel conflict and legal disputes.

4. Unconsidered Alternative

AMI failed to consider a Private Label or OEM strategy for the Tier 3 market. By stripping the AMI brand and advanced features from a base model CT scanner and selling it through distributors under a value brand, AMI could protect its premium brand positioning in Tier 1 while aggressively competing on price in the clinic market without any risk of channel overlap.